Thomas Shiovitz

4.6k total citations
28 papers, 1.2k citations indexed

About

Thomas Shiovitz is a scholar working on Pharmacology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Thomas Shiovitz has authored 28 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pharmacology, 12 papers in Psychiatry and Mental health and 4 papers in Molecular Biology. Recurrent topics in Thomas Shiovitz's work include Treatment of Major Depression (7 papers), Cholinesterase and Neurodegenerative Diseases (6 papers) and Schizophrenia research and treatment (6 papers). Thomas Shiovitz is often cited by papers focused on Treatment of Major Depression (7 papers), Cholinesterase and Neurodegenerative Diseases (6 papers) and Schizophrenia research and treatment (6 papers). Thomas Shiovitz collaborates with scholars based in United States, Denmark and Switzerland. Thomas Shiovitz's co-authors include Neal R. Cutler, Jeffrey Miceli, John J. Sramek, Richard Anziano, Stanford S. Jhee, Edmund P. Harrigan, Karen R. Reeves, Michelle V. Middle, Eric Watsky and Edyta J. Frackiewicz and has published in prestigious journals such as American Journal of Psychiatry, Neurology and Schizophrenia Bulletin.

In The Last Decade

Thomas Shiovitz

26 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Shiovitz United States 16 554 303 184 179 167 28 1.2k
Padideh Ghaeli Iran 20 417 0.8× 200 0.7× 80 0.4× 144 0.8× 121 0.7× 76 1.2k
Margaret A. Kirshner United States 26 946 1.7× 480 1.6× 297 1.6× 148 0.8× 94 0.6× 40 2.1k
Mehrul Hasnain United States 20 692 1.2× 587 1.9× 456 2.5× 242 1.4× 231 1.4× 35 1.9k
M. Fava United States 11 351 0.6× 366 1.2× 153 0.8× 263 1.5× 215 1.3× 12 1.0k
Sanjay Gupta United States 27 1.2k 2.2× 396 1.3× 141 0.8× 346 1.9× 135 0.8× 109 2.3k
Dan Zimbroff United States 12 890 1.6× 266 0.9× 63 0.3× 317 1.8× 147 0.9× 21 1.3k
R. Grohmann Germany 26 1.3k 2.4× 436 1.4× 198 1.1× 311 1.7× 150 0.9× 130 2.0k
Lars Tanum Norway 18 659 1.2× 370 1.2× 64 0.3× 138 0.8× 94 0.6× 77 1.6k
Amber N. Edinoff United States 20 283 0.5× 292 1.0× 96 0.5× 122 0.7× 101 0.6× 88 1.5k
Philipp Rothe Germany 10 1.1k 1.9× 242 0.8× 62 0.3× 234 1.3× 119 0.7× 17 1.4k

Countries citing papers authored by Thomas Shiovitz

Since Specialization
Citations

This map shows the geographic impact of Thomas Shiovitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Shiovitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Shiovitz more than expected).

Fields of papers citing papers by Thomas Shiovitz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Shiovitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Shiovitz. The network helps show where Thomas Shiovitz may publish in the future.

Co-authorship network of co-authors of Thomas Shiovitz

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Shiovitz. A scholar is included among the top collaborators of Thomas Shiovitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Shiovitz. Thomas Shiovitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Croop, Robert, Thomas Shiovitz, Arifulla Khan, et al.. (2022). An Open-label, Intermediate-sized, Expanded Access Protocol of Rimegepant in the Acute Treatment of Migraine (P2-2.006). Neurology. 98(18_supplement). 1 indexed citations
2.
Shiovitz, Thomas, et al.. (2020). The Patient in Your Alzheimer's Disease Study May be in Another: Duplication and Deception in Clinical Trials of Alzheimer's Disease. The Journal of Prevention of Alzheimer s Disease. 7(1). 43–46. 1 indexed citations
3.
O’Gorman, Cullen, Rita Khoury, Ariana Anderson, et al.. (2020). A Framework for Developing Pharmacotherapy for Agitation in Alzheimer's disease: Recommendations of the ISCTM Working Group. The Journal of Prevention of Alzheimer s Disease. 7(4). 274–282. 6 indexed citations
4.
Shiovitz, Thomas, Earle Bain, David J. McCann, et al.. (2015). Mitigating the Effects of Nonadherence in Clinical Trials. The Journal of Clinical Pharmacology. 56(9). 1151–1164. 79 indexed citations
5.
Shiovitz, Thomas, et al.. (2014). A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder.. PubMed. 11(1-2). 10–22. 22 indexed citations
6.
Rickels, Karl, et al.. (2012). Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. International Clinical Psychopharmacology. 27(3). 142–150. 44 indexed citations
7.
8.
Miceli, Jeffrey, et al.. (2010). Effects of Oral Ziprasidone and Oral Haloperidol on QTc Interval in Patients with Schizophrenia or Schizoaffective Disorder. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 30(2). 127–135. 29 indexed citations
9.
Mohs, Richard C., et al.. (2009). Atomoxetine Augmentation of Cholinesterase Inhibitor Therapy in Patients With Alzheimer Disease: 6-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel-Trial Study. American Journal of Geriatric Psychiatry. 17(9). 752–759. 43 indexed citations
10.
Miceli, J., et al.. (2009). P.4.a.015 Adjunctive pregabalin after partial response to SSRI or SNRI in GAD: results of a double-blind, placebo-controlled trial. European Neuropsychopharmacology. 19. S593–S594. 1 indexed citations
11.
Harrigan, Edmund P., Jeffrey Miceli, Richard Anziano, et al.. (2004). A Randomized Evaluation of the Effects of Six Antipsychotic Agents on QTc, In the Absence and Presence of Metabolic Inhibition. Journal of Clinical Psychopharmacology. 24(1). 62–69. 258 indexed citations
12.
Schneider, Lon S., J. Craig Nelson, Cathryn M. Clary, et al.. (2003). An 8-Week Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled Study of Sertraline in Elderly Outpatients With Major Depression. American Journal of Psychiatry. 160(7). 1277–1285. 124 indexed citations
13.
Jhee, Stanford S., Laura Fabbri, Susan Moran, et al.. (2003). First Clinical Evaluation of Ganstigmine in Patients With Probable Alzheimer's Disease. Clinical Neuropharmacology. 26(3). 164–169. 6 indexed citations
14.
Hossain, Mohammad Sharif, Stanford S. Jhee, Thomas Shiovitz, et al.. (2002). Estimation of the Absolute Bioavailability of Rivastigmine in Patients with Mild to Moderate Dementia of the Alzheimer???s Type. Clinical Pharmacokinetics. 41(3). 225–234. 50 indexed citations
15.
Frackiewicz, Edyta J. & Thomas Shiovitz. (2001). Evaluation and Management of Premenstrual Syndrome and Premenstrual Dysphoric Disorder. Journal of the American Pharmaceutical Association (1996). 41(3). 437–447. 42 indexed citations
16.
Jhee, Stanford S., Thomas Shiovitz, Aaron W. Crawford, & Neal R. Cutler. (2001). Pharmacokinetics and Pharmacodynamics of the Triptan Antimigraine Agents. Clinical Pharmacokinetics. 40(3). 189–205. 87 indexed citations
17.
Salazar, Daniel E., Edyta J. Frackiewicz, Randy Dockens, et al.. (2001). Pharmacokinetics and Tolerability of Buspirone during Oral Administration to Children and Adolescents with Anxiety Disorder and Normal Healthy Adults. The Journal of Clinical Pharmacology. 41(12). 1351–1358. 27 indexed citations
18.
Pande, Atul C., Mark H. Pollack, Jerri G. Crockatt, et al.. (2000). Placebo-Controlled Study of Gabapentin Treatment of Panic Disorder. Journal of Clinical Psychopharmacology. 20(4). 467–471. 212 indexed citations
19.
Cutler, Neal R., Gary Friday, Lloyd Haskell, et al.. (1999). NXX-066 IN ALZHEIMER PATIENTS: A BRIDGING STUDY. American Journal of Geriatric Psychiatry. 7. 58–58. 1 indexed citations
20.
Shiovitz, Thomas, et al.. (1996). Cholinergic Rebound and Rapid Onset Psychosis Following Abrupt Clozapine Withdrawal. Schizophrenia Bulletin. 22(4). 591–595. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Padideh Ghaeli Breakdown of academic impact, for papers by Margaret A. Kirshner Breakdown of academic impact, for papers by Mehrul Hasnain Breakdown of academic impact, for papers by M. Fava Breakdown of academic impact, for papers by Sanjay Gupta Breakdown of academic impact, for papers by Dan Zimbroff Breakdown of academic impact, for papers by R. Grohmann Breakdown of academic impact, for papers by Lars Tanum Breakdown of academic impact, for papers by Amber N. Edinoff Breakdown of academic impact, for papers by Philipp Rothe
Rankless by CCL
2026